Test first if you eat fish, supplement first if you don't. The Omega-3 Index is the better-validated of the two: a pooled analysis of 17 prospective cohorts links higher blood omega-3 to lower mortality, while standard supplement doses failed to prevent cardiovascular events in VITAL and STRENGTH. Above 1 g/day there is a real atrial-fibrillation signal. Two oily-fish meals a week move the index about as much as a capsule.
| Compared on | Fish oil (EPA/DHA) | Omega-3 Index test |
|---|---|---|
| Evidence grade | Moderate evidence | Measurement tool |
| What it is | Omega-3 fatty acids are long-chain polyunsaturated fats, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found mainly in oily fish and fish oil; a plant-derived form, alpha-linolenic acid (ALA), occurs in walnuts and flaxseed. | The Omega-3 Index is a blood biomarker defined as the amount of the long-chain marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) contained in red blood cell (erythrocyte) membranes, expressed as a percentage of total fatty acids. |
| Best human evidence | “increasing omega-3 slightly reduces risk of coronary heart disease mortality and reduces triglycerides” Cochrane Database Syst Rev 2020 · PMID 32114706 | “risk for death from all causes was significantly lower (by 15-18%, at least p < 0.003) in the highest vs the lowest quintile for circulating long chain (20-22 carbon) omega-3 fatty acids…” Nat Commun 2021 · PMID 33888689 |
| Dose / protocol studied | Typical studied range 0.5-4 g/day EPA+DHA; triglyceride and blood-pressure effects are dose-dependent, clearest around 2-3 g/day. Event-reduction evidence is for prescription 4 g/day purified EPA in high-risk patients. | Once to find your baseline, then again about 4 months after changing oily fish intake or starting a supplement - red cell fatty acids turn over slowly and anything sooner is reading noise. Most people sit around 4-5%; the level associated with lowest risk in the cohort work is roughly 8% or above. |
| Price | $33.75 Typical listed price | $54.95 Cost per test |
| Who it suits | Someone who eats little or no oily fish, or who has high triglycerides and is working with a clinician on them. | Someone who wants to know whether they need a supplement at all, or who has changed their fish intake and wants to see whether it landed. |
| Who should skip it | A healthy person taking more than 1 g/day for prevention: large trials were neutral for events and the atrial-fibrillation risk rises with dose. | Anyone who will re-test sooner than about four months — red-cell fatty acids turn over slowly and anything faster is reading noise. |
| Key caveat | Standard over-the-counter doses did not prevent cardiovascular events or cancer in large trials (VITAL, STRENGTH) and meta-analyses, though triglyceride lowering is real. Doses above 1 g/day carry a genuine atrial-fibrillation signal - about 13% higher incident risk in a large cohort of healthy users. | This is the one test on the list where the analyte and the method were developed together and both hold up. Pooled across 17 prospective cohorts, higher blood omega-3 levels tracked lower total and cause-specific mortality, the Framingham data point the same way, and the index adds predictive information on top of the pooled cohort equation - and unlike a serum fatty acid, red cell membrane composition is a stable several-month average rather than a… |
Omega-3 Index test lists at about 1.6× the price of Fish oil (EPA/DHA). Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
This is the rare pairing where the test is better evidenced than the thing it measures the effect of.
Test, don't supplement. Your blood omega-3 level is set mainly by how much fish you eat, and two or more seafood meals a week raises the index much like a supplement does. A test tells you whether you have anything to fix.
Supplement, then test in four months. Most people sit around 4–5% on the index; the level associated with lowest risk in the cohort work is roughly 8% or above. Testing a baseline you can already predict is less useful than testing whether the change worked.
Talk to a clinician about dose. Triglyceride lowering is the most consistent effect — roughly 15% at higher doses, clearest around 2–3 g/day — and the event-reduction evidence is for prescription 4 g/day purified EPA in high-risk statin-treated patients, not for over-the-counter capsules.
Neither without medical advice. A meta-analysis of cardiovascular-outcome trials found marine omega-3 supplementation associated with increased atrial-fibrillation risk, greater in trials testing more than 1 g/day, and a UK Biobank cohort of 415,737 people found a 13% higher incidence in users without cardiovascular disease.
The Omega-3 Index is a proprietary measure run by the laboratory whose founder developed it and co-authors much of the supporting literature. That is disclosed rather than hidden, but it is not an independently standardised assay with an external reference method behind it.
And the evidence is observational: people with a high index differ from people with a low one in many ways, and the supplement trials designed to test whether raising it changes outcomes came out mixed rather than clean. A low number is a reason to eat more oily fish, not proof that a capsule buys you the associated risk reduction.
Cited: JAMA 2020 · PMID 33190147
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“increasing omega-3 slightly reduces risk of coronary heart disease mortality and reduces triglycerides”
“In 13,078 high-risk patients (STRENGTH), 4 g/day EPA+DHA carboxylic acids showed no cardiovascular benefit over corn oil (HR 0.99), with more atrial fibrillation in the omega-3 group.”
“In RCTs examining cardiovascular outcomes, marine ɷ-3 supplementation was associated with an increased risk of AF. The risk appeared to be greater in trials testing >1 g/d.”
“risk for death from all causes was significantly lower (by 15-18%, at least p < 0.003) in the highest vs the lowest quintile for circulating long chain (20-22 carbon) omega-3 fatty acids (eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids).”
“The Omega-3 Index was inversely associated with risk for CHD mortality. An Omega-3 Index of > or = 8% was associated with the greatest cardioprotection, whereas an index of < or = 4% was associated with the least.”
“Those in the highest (>6.8%) compared to those in the lowest Omega-3 Index quintiles (<4.2%) had a 34% lower risk for death from any cause and 39% lower risk for incident CVD.”
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
If you already eat oily fish regularly, yes — you may not need a supplement at all. If you never eat fish, your index is very likely low, and testing a predictable baseline is less useful than supplementing and re-testing about four months later.
Commonly cited target values are 8–11%. Across ten cohorts an index near 8% carried roughly 30% lower fatal coronary heart disease risk than one near 4%. Most people sit around 4–5%.
Not at standard over-the-counter doses. VITAL found little overall benefit at 1 g/day, STRENGTH found high-dose EPA+DHA no better than corn oil, and Cochrane concluded supplements have little or no effect on all-cause or cardiovascular mortality. High-dose purified EPA reduced ischemic events in REDUCE-IT in a specific high-risk statin-treated population.
Once to find your baseline, then again about four months after changing oily-fish intake or starting a supplement. Red-cell fatty acids turn over slowly, so testing sooner reads noise.
Ask your clinician for the panel first — it is the cheaper, standardised measurement, and non-HDL…
If you don't have diabetes, probably neither. The 25-trial meta-analysis of CGM as a behaviour-change tool…
Home cuff for almost everyone. Both measure out-of-office pressure, which predicts outcomes better than a…